Blue Owl Capital Holdings LP Purchases 375,000 Shares of Compass Pathways PLC Sponsored ADR $CMPS

Blue Owl Capital Holdings LP increased its position in Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) by 163.1% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 604,914 shares of the company’s stock after purchasing an additional 375,000 shares during the period. Compass Pathways accounts for 1.1% of Blue Owl Capital Holdings LP’s portfolio, making the stock its 27th biggest position. Blue Owl Capital Holdings LP’s holdings in Compass Pathways were worth $3,466,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. lifted its position in Compass Pathways by 46.7% during the second quarter. China Universal Asset Management Co. Ltd. now owns 18,272 shares of the company’s stock valued at $51,000 after buying an additional 5,817 shares during the period. BIT Capital GmbH purchased a new stake in shares of Compass Pathways in the 3rd quarter worth about $54,000. Northeast Financial Consultants Inc purchased a new stake in shares of Compass Pathways in the 2nd quarter worth about $59,000. CWM LLC increased its stake in shares of Compass Pathways by 19.2% in the 3rd quarter. CWM LLC now owns 15,650 shares of the company’s stock worth $90,000 after acquiring an additional 2,525 shares in the last quarter. Finally, Zhang Financial LLC bought a new position in shares of Compass Pathways during the third quarter valued at approximately $109,000. Institutional investors own 46.19% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on CMPS shares. Royal Bank Of Canada lifted their target price on shares of Compass Pathways from $21.00 to $22.00 and gave the company an “outperform” rating in a report on Wednesday, February 18th. Lifesci Capital raised Compass Pathways to a “strong-buy” rating in a research report on Thursday, February 12th. Canaccord Genuity Group raised their price objective on Compass Pathways from $15.00 to $20.00 and gave the company a “buy” rating in a research report on Wednesday, February 18th. Morgan Stanley boosted their target price on Compass Pathways from $11.00 to $18.00 and gave the stock an “overweight” rating in a report on Wednesday, February 18th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Compass Pathways in a research note on Wednesday, January 21st. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Compass Pathways presently has an average rating of “Moderate Buy” and a consensus price target of $22.13.

Compass Pathways Trading Down 2.9%

Shares of NASDAQ:CMPS opened at $6.58 on Friday. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.23 and a quick ratio of 1.23. Compass Pathways PLC Sponsored ADR has a 1 year low of $2.25 and a 1 year high of $8.90. The company has a market cap of $631.81 million, a P/E ratio of -2.42 and a beta of 1.90. The stock’s fifty day moving average price is $6.98 and its 200-day moving average price is $6.15.

Compass Pathways Company Profile

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.